Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

Vergnenègre, A.; Smit, Egbert F.; Toy, Elisabeth; Parente, Bárbara; Schmitz, Stephan; Kraaij, Kees; Soldatenkova, Victoria; Visseren‐Grul, Carla; Zanotti, Giovanni; Taipale, Kaisa; Moro-Sibilot, Denis

doi:10.1185/03007995.2012.703133

Cited by 10 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the Japanese study, single-agent targeted therapy was the most commonly prescribed second-line treatment [13]. Docetaxel, pemetrexed, and gemcitabine were among the top 3 most frequently used single-agent chemotherapeutics across the studies [15–22, 24–27]. In Japan gefitinib was the most frequently used second-line single-agent targeted-therapy [13].…”

Section: Resultsmentioning

confidence: 99%

“…In Japan gefitinib was the most frequently used second-line single-agent targeted-therapy [13]. Outside of Asia, the most frequently used single-agent targeted therapy was erlotinib [15–19, 22, 24, 25, 27]. …”

Section: Resultsmentioning

confidence: 99%

“…Pemetrexed was one of the most commonly prescribed second-line treatments in the studies that included patients treated after its initial approval in 2004 [15–18, 22, 24, 25, 27]. The study conducted in Canada reported that pemetrexed use increased to 70% among treated second-line patients in 2008, when government funding was approved for pemetrexed [20].…”

Section: Resultsmentioning

confidence: 99%

“…Second-line treatment with EGFR-TKIs increased in the European studies after initial approval of erlotinib in 2005 [15–19, 21, 22, 24, 25]. This uptake occurred prior to the widespread introduction of EGFR mutation testing, which was not required at the time of initial erlotinib approval.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

et al. 2017

View full text Add to dashboard Cite

Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC. In light of these approvals, it is valuable to understand the uptake of these new treatments in routine clinical practice and their impact on patient care. A systematic literature search was conducted in multiple scientific databases to identify observational cohort studies published between January 2010 and March 2017 that described second- or third-line treatment patterns and clinical outcomes in patients with advanced NSCLC. A qualitative data synthesis was performed because a meta-analysis was not possible due to the heterogeneity of the study populations. A total of 12 different study cohorts in 15 articles were identified. In these cohorts, single-agent chemotherapy was the most commonly administered treatment in both the second- and third-line settings. In the 5 studies that described survival from the time of second-line treatment initiation, median overall survival ranged from 4.6 months (95% CI, 3.8–5.7) to 12.8 months (95% CI, 10.7–14.5). There was limited information on the use of biomarker-directed therapy in these patient populations. This systematic literature review offers insights into the adoption of novel therapies into routine clinical practice for second- and third-line treatment of patients with advanced NSCLC. This information provides a valuable real-world context for the impact of recently approved treatments for advanced NSCLC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The inclusion of approximately 150–200 patients per country in the first‐line setting was planned on the basis of precision estimates and attrition rates around the primary objective. Prior real‐world studies have reported that approximately 39% of patients who receive first‐line therapy will receive second‐line therapy (Bischoff et al., 2010; Gerber et al., 2011; Vergnenegre et al., 2012), and 22% of patients who receive second‐line therapy will receive third‐line therapy (Pan, Mallick, Dhanda, & Nadler, 2013). …”

Section: Methodsmentioning

confidence: 99%

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

et al. 2017

View full text Add to dashboard Cite

The aim of this multinational retrospective cohort study, conducted at academic and community oncology centres, was to describe real‐world treatment patterns for patients with a confirmed diagnosis of advanced/metastatic (stage IIIB/IV) non‐small cell lung cancer (NSCLC) who initiated first‐line systemic therapy from January 2011 through June 2014. The study included 1265 patients in Italy, Spain, Germany, Australia, Korea, Taiwan and Brazil. The proportion of patients with squamous versus non‐squamous NSCLC was approximately 20% versus 75%, and associated patient demographic characteristics were similar in all countries, excepting race. Patients with squamous NSCLC were predominantly male and current/ex‐smokers. Biomarker tests were performed for the majority of patients with non‐squamous NSCLC, ranging from 54% (Brazil) to 91% in Taiwan, where, of those tested, 68% with non‐squamous NSCLC had positive epidermal growth factor receptor (EGFR)‐mutation status; in other countries the EGFR‐positive percentages ranged from 17% (Spain/Brazil) to 40% (Korea). Platinum‐based regimens were the most common first‐line therapy in all countries except Taiwan, where gefitinib was the most common first‐line agent. Median overall survival ranged from 9.3 months (Brazil) to 25.5 months (Taiwan). The diagnostic and treatment patterns recorded in this study were heterogeneous but largely in line with NSCLC guidelines during the study period.

show abstract

Identifying Subsequent Therapies in Patients with Advanced Non–Small Cell Lung Cancer and Factors Associated with Overall Survival

et al. 2016

View full text Add to dashboard Cite

show abstract

Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

Cited by 10 publications

References 32 publications

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

Identifying Subsequent Therapies in Patients with Advanced Non–Small Cell Lung Cancer and Factors Associated with Overall Survival

Contact Info

Product

Resources

About